DONATE TODAY
May 29, 2019

Rebound of medication abortion in Texas following updated mifepristone label

In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.
Share
Facebook
LinkedIn
X

Rebound of medication abortion in Texas following updated mifepristone label

https://doi.org/10.1016/j.contraception.2019.01.001

Details
Date
May 29, 2019
Category
Abortion Care
Journal
The journal Contraception
Authors
Sarah E. Baum, Kari White, Kristine Hopkins, Joseph E. Potter, Daniel Grossman
key findings
Citation
Related Publications

Changes in Facility-Based Abortion Care Among Texas Resident Minors and Young Adults After a 2021 Abortion Ban: September 2020-May 2022

Abortion Care, Journal Articles, Policy Analysis, Texas

Perspectives on options for self-sourcing medication abortion after implementation of Texas Senate Bill 8

Abortion Care, Providers, Systems of Care, Texas

Preferred strategies for obtaining abortion care among pregnant Texans: a latent class analysis

Abortion Care, Journal Articles, Texas

Time Pressures and Sociocultural Constraints Affecting Access to Early Abortion Care Under Texas’ “6‑Week” Ban

Abortion Care, Systems of Care, Texas

Contact Us

  • 737-381-1260
  • info@resoundrh.org

Advancing equitable reproductive health through rigorous research.

© 2024 Resound Research for Reproductive Health is fiscally sponsored by The Tides Center

PRIVACY POLICY
TERMS OF USE